Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01654068Not ApplicableTerminated

Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine

Role: lead

NCT03029416Phase 2Withdrawn

Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension

Role: lead

NCT01657617Not ApplicableCompleted

Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer

Role: lead

All 3 trials loaded